Loading
A phase 2 trial of Durvalumab in hepatocellular carcinoma, run by Boston Scientific Corporation, active and no longer recruiting.
TheraSphere With Durvalumab and Tremelimumab for HCC is a phase 2 interventional study registered as NCT05063565 by Boston Scientific Corporation, with 100 participants planned, started 2023-11-03 and due to reach its primary completion in 2027-06. Interventions recorded: TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.
Shares Durvalumab, Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Durvalumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/